相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atogepant: First Approval
Emma D. Deeks
DRUGS (2022)
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
Xinyu Tao et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
Fred Cohen et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2022)
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2022)
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
K. Chris Min et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis
Prashant Soni et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2021)
Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials
Chun-Pai Yang et al.
NEUROTHERAPEUTICS (2021)
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
Shuu-Jiun Wang et al.
CEPHALALGIA (2021)
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients
Fumihiko Sakai et al.
HEADACHE (2021)
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Takao Takeshima et al.
HEADACHE (2021)
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials
Ahmed Taher Masoud et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)
Atogepant for the Preventive Treatment of Migraine
Jessica Ailani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies
Jingjing Xu et al.
CEPHALALGIA (2020)
Co-occurrence of pain syndromes
Giannapia Affaitati et al.
JOURNAL OF NEURAL TRANSMISSION (2020)
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina et al.
CEPHALALGIA (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application
Silvia Minozzi et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Wim M. Mulleners et al.
LANCET NEUROLOGY (2020)
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
Peter J. Goadsby et al.
LANCET NEUROLOGY (2020)
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
David W. Dodick et al.
CEPHALALGIA (2019)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
Fumihiko Sakai et al.
HEADACHE (2019)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Messoud Ashina et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Migraine is first cause of disability in under 50s: will health politicians now take notice?
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
Vladimir Skljarevski et al.
JAMA NEUROLOGY (2018)
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment
Stewart J. Tepper
HEADACHE (2018)
Myofascial trigger points in migraine and tension-type headache
Thien Phu Do et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018
Stewart J. Tepper
HEADACHE (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke et al.
NEUROLOGY (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Sex-Related Influences in Migraine
Jelena M. Pavlovic et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2017)
Fibromyalgia Among Patients With Chronic Migraine and Chronic Tension-Type Headache: A Multicenter Prospective Cross-Sectional Study
Soo-Jin Cho et al.
HEADACHE (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Telcagepant-almost gone, but not to be forgotten (invited editorial related to Ho etal., 2015)
P. Christopher H. Gottschalk
CEPHALALGIA (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
Richard B. Lipton et al.
HEADACHE (2015)
Pain thresholds in women with chronic pelvic pain
Maria A. Giamberardino et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain
Rodrigo Noseda et al.
PAIN (2013)
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. D. Silberstein et al.
NEUROLOGY (2012)
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
David J. Hewitt et al.
CEPHALALGIA (2011)
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
Jakob Moller Hansen et al.
CEPHALALGIA (2010)
Tracing transformation Chronic migraine classification, progression, and epidemiology
Richard B. Lipton
NEUROLOGY (2009)
Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study
Marcelo E. Bigal et al.
HEADACHE (2008)
Fibromyalgia is common in patients with transformed migraine
MFP Peres et al.
NEUROLOGY (2001)
分享论文
